GlassScriptPhysician profile
Carlos Gadea
NPI 1235257668
$18,143.20
in general payments reported to CMS, 2019-2025
74 companies · $3,377 in 2025
The $3,377 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,419 · 2020: $1,265 · 2021: $2,539 · 2022: $2,681 · 2023: $3,346 · 2024: $3,515 · 2025: $3,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,552 · Education: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,551.73 |
| Education | $687.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,230.45 | 2019-2025 | |
| Astellas Pharma US INC | $1,175.27 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Janssen Biotech, INC. | $1,159.93 | 2020-2025 | Erleada, Balversa, Akeega |
| Merck Sharp & Dohme LLC | $1,129.71 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $1,102.32 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Pfizer INC. | $998.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $997.97 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $936.42 | 2019-2025 | Opdivo, Reblozyl |
| Celgene Corporation | $849.31 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Lilly USA, LLC | $743.09 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $604.25 | 2019-2025 | |
| Seagen INC. | $517.33 | 2020-2024 | Tukysa, Adcetris |
| Daiichi Sankyo INC. | $509.80 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Eisai INC. | $474.82 | 2020-2025 | |
| Karyopharm Therapeutics INC. | $373.87 | 2020-2025 | Xpovio |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Gadea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.